- Home
- SGU vs OLMA Comparison
SGU vs OLMA Comparison
Compare SGU & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGU
- OLMA
- Stock Information
- Founded
- SGU 1995
- OLMA 2006
- Country
- SGU United States
- OLMA United States
- Employees
- SGU N/A
- OLMA N/A
- Industry
- SGU Other Specialty Stores
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- SGU Consumer Discretionary
- OLMA Health Care
- Exchange
- SGU Nasdaq
- OLMA Nasdaq
- Market Cap
- SGU 406.3M
- OLMA 465.4M
- IPO Year
- SGU 1995
- OLMA 2020
- Fundamental
- Price
- SGU $11.52
- OLMA $6.15
- Analyst Decision
- SGU
- OLMA Strong Buy
- Analyst Count
- SGU 0
- OLMA 5
- Target Price
- SGU N/A
- OLMA $26.25
- AVG Volume (30 Days)
- SGU 23.2K
- OLMA 1.1M
- Earning Date
- SGU 02-05-2025
- OLMA 11-12-2024
- Dividend Yield
- SGU 5.96%
- OLMA N/A
- EPS Growth
- SGU 10.70
- OLMA N/A
- EPS
- SGU 0.90
- OLMA N/A
- Revenue
- SGU $1,766,099,000.00
- OLMA N/A
- Revenue This Year
- SGU N/A
- OLMA N/A
- Revenue Next Year
- SGU N/A
- OLMA N/A
- P/E Ratio
- SGU $12.88
- OLMA N/A
- Revenue Growth
- SGU N/A
- OLMA N/A
- 52 Week Low
- SGU $9.64
- OLMA $5.56
- 52 Week High
- SGU $12.93
- OLMA $16.78
- Technical
- Relative Strength Index (RSI)
- SGU 43.16
- OLMA 28.87
- Support Level
- SGU $11.13
- OLMA $5.56
- Resistance Level
- SGU $11.63
- OLMA $6.49
- Average True Range (ATR)
- SGU 0.32
- OLMA 0.75
- MACD
- SGU -0.03
- OLMA -0.05
- Stochastic Oscillator
- SGU 41.24
- OLMA 11.68
About SGU Star Group L.P.
Star Group LP is a company engaged in providing home heating products and services to residential and commercial customers. The company offers heating oil and air conditioning equipment, as well as home security and plumbing services. The company also sells diesel fuel, gasoline, and home heating oil. Geographically, the company operates in U.S.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.